-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA: APPROVES GEDATOLISIB WITH FULVESTRANT, WITH OR WITHOUT PALBOCICLIB, FOR HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Reuters·07/14/2026 19:20:28

Please log in to view news